Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas

Trial Profile

Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
    • 18 Jun 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
    • 09 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top